FORMULATION DEVELOPMENT AND EVALUATION OF ORODISPERSIBLE TABLET OF CINNARIZINE SOLID DISPERSION

The objective of present study was to formulate directly compressible orodispersible tablets of Cinnarizine with improved solubility and bioavailability by using solid dispersion technique. Cinnarizine is a H1 receptor antagonist and widely used in the treatment of motion sickness, vomiting and vertigo disorder. Solid dispersion of Cinnarizine was prepared by Solvent evaporation method and physical mixture using novel polymer soluplus as carrier. 1:1, 1:2 and 1:3 these three different weight ratios of drug and carrier respectively were taken. Saturation solubility of drug was determined in physical mixture and solid dispersion formulation. The prepared solid dispersion formulations were further characterized by drug contents, FTIR spectroscopy, DSC and in-vitro drug release. From that crystalline form of Cinnarizine is converted into amorphous state during formulation of solid dispersion. Solid dispersion by solvent evaporation method in 1:3 ratios showed better results than other formulations. Orodispersible tablets of Cinnarizine were compressed using selected solid dispersion 1:3 formulation and excipients with kyron T 314 as a superdisintegrant. Orodispersible tablet shows disintegration time 13 seconds and in-vitro drug release 99.75 %, which is better as compare to marketed conventional tablet 66.92 % within 15 minutes. Thus formulation of orodispersible tablet of Cinnarizine solid dispersion showed increased solubility and bioavailability with patient complies and convenience. Keywords: Cinnarizine, Soluplus, Kyron T-314, Solid dispersion, Orodispersible tablet, Solubility.